AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23660721
Drug: Distributed training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed training group with five monthly unsupervised training sessions of 30 min on the LapMentor(®) (group 4)
Trial: 22057609
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing plus photodynamic therapy (Sc/Rp + PDT)
Trial: 18845008
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Cognitive Behavioral Therapy (CBT)
Trial: 12878920
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Cognitive Behavioral Therapy (CBT)
Trial: 15293581
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous morphine and procedural information
Trial: 15293581
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous ketorolac and procedural information
Trial: 15293581
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous morphine plus procedural and sensory information
Trial: 15293581
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous ketorolac plus procedural and sensory information
Trial: 15293581
Drug: All interventions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All interventions (morphine and ketorolac)
Trial: 8089357
Drug: Topical EMLA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical EMLA
Trial: 9417009
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo (no anesthetic)
Trial: 7619991
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of fluconazole (group B)
Trial: 7619991
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous administration of amphotericin B (group C)
Trial: 2571625
Drug: Trauma desensitization,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma desensitization, hypnotherapy, and psychodynamic therapy
Trial: 346292
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or Placebo
Trial: 28646812
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 supplementation (300 mg/d for weeks 1-4, 150 mg/d for weeks 5-8)
Trial: 28646812
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rice flour placebo, similar dosing to intervention group)
Trial: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 200 mg (Arm B)
Trial: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 400 mg (Arm C)
Trial: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, placebo (Arm A)
Trial: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination
Trial: 8884875
Drug: Clodronate (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (800 mg orally four times daily)
Trial: 8884875
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (280 mg orally twice daily)
Trial: 1669598
Drug: Local immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local immunotherapy (LI) by inhalation of a powder extract of house dust mite (HDM)
Trial: 1669598
Drug: Parenteral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral immunotherapy (PI) by injection
Trial: 6601670
Drug: SRW intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRW intranasal immunotherapy (n = 11); cumulative AgE doses from 3 to 59 micrograms (mean 21)
Trial: 30840130
Drug: Uninterrupted apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Uninterrupted apixaban therapy (Group 1, n=32)
Trial: 30840130
Drug: Interrupted apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interrupted apixaban therapy (Group 2, n=65)
Trial: 29235300
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine and Western medicine treatment (Buxin Yishen decoction)
Trial: 29235300
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine treatment (control group)
Trial: 24435207
Drug: Silodosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (8 mg/day for 6 months)
Trial: 19079954
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment combined with cognitive-behavioral therapy (CBT)
Trial: 11719017
Drug: Eudragit L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eudragit L 30 D‐55 coated capsules
Trial: 11719017
Drug: Eudragit FS
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eudragit FS 30 D coated capsules
Trial: 9620358
Drug: Anti-CD3 monoclonal
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in young humans
Trial: 9620358
Drug: Anti-CD3 monoclonal
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in elderly humans
Trial: 7616847
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous Intralipid infusion (test 1)
Trial: 7616847
Drug: Heparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (30 U/min) plus low-dose Intralipid infusion (test 2)
Trial: 10532694
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion
Trial: 1969013
Drug: Heparin bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bolus
Trial: 6448885
Drug: L-Deprenil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Deprenil plus L-5-HTP and benzerazide
Trial: 6448885
Drug: L-5-HTP and
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-HTP and benzerazide
Trial: 29081098
Drug: Alanyl glutamine
RxNorm normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl glutamine injection plus conventional therapy
Trial: 26480877
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 2 g by topical application
Trial: 23596780
Drug: Shenyan Kangfu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyan Kangfu Tablet (SKT)
Trial: 19180358
Drug: Trehalose/Fructose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose/Fructose combination
Trial: 17192336
Drug: C-peptide 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide 1.5 mg/day (divided into four subcutaneous doses) for 6 months
Trial: 17192336
Drug: C-peptide 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide 4.5 mg/day for 6 months
Trial: 17192336
Drug: C-peptide treatment
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide treatment
Trial: 7945477
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg/kg/day)
Trial: 6127968
Drug: Diazepam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.15 mg/kg
Trial: 11682416
Drug: Meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.5 mg/kg
Trial: 29723220
Drug: Cognitive dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive dysfunction in SLE patients with positive IgG anticardiolipin antibodies (50%) compared to normal cognitive function (18%), P = 0.009
Trial: 29723220
Drug: CCL2 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCL2 levels in CSF of SLE patients with cognitive dysfunction [886.1 (374.9–1439.7) pg/mL] compared to normal cognitive function [515.8 (3.2–1958.2) pg/mL], P = 0.04
Trial: 28870217
Drug: MPA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (10 mg) administered daily from early follicular phase
Trial: 26216383
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg i.v. q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin (PLD 30 mg/m2 or doxorubicin 50 mg/m2 i.v., day 1, q4 weeks, for six cycles)
Trial: 26216383
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg i.v. q4 weeks
Trial: 22218118
Drug: Losartan, 25
RxNorm normalized name: Hydrochlorothiazide-Losartan, 25 mg-100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 25 mg, twice per day
Trial: 22218118
Drug: Losartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan + N-acetyl cysteine (NAC), 600 mg twice daily
Trial: 964138
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (Kopenhagen strain) at 160.000 organisms per dose
Trial: 964138
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (Kopenhagen strain) at lower concentrations (22.000, 50.000, 110.000 organisms per dose)
Trial: 29468715
Drug: AZD9977 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977 (5 to 1200 mg)
Trial: 29468715
Drug: AZD9977/eplerenone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977/eplerenone combination
Trial: 26827266
Drug: Rufinamide therapy
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide therapy
Trial: 20357504
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa seed supplementation (2 g/day orally) for 30 days
Trial: 20357504
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 ml saline solution subcutaneously once a week)
Trial: 28589947
Drug: EGCG+RES (epigallocatechin‐3‐gallate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG+RES (epigallocatechin‐3‐gallate and resveratrol, 282 and 80 mg/day, respectively)
Trial: 21103659
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg and placebo (n=68)
Trial: 21103659
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg and aspirin 100 mg (n=63)
Trial: 21103659
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg (n=76)
Trial: 19033877
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (cutaneous anesthesia) applied to the lower leg
Trial: 17939194
Drug: Vegetotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetotropic therapy (Propranolol, Metoclopramid, Atropine)
Trial: 2688937
Drug: Artemisinin suppositories
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin suppositories (2800 mg for 3 days)
Trial: 1287904
Drug: Artemisinin suppositories
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin suppositories
Trial: 21600005
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplement (MMS) at two times the recommended dietary allowance (RDA)
Trial: 21600005
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care supplement of 6 multivitamins (MV)
Trial: 9249883
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of furosemide (twice daily)
Trial: 9249883
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide (over 24 hours)
Trial: 9249883
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of furosemide
Trial: 8491934
Drug: Antimicrobial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial treatment (amoxicillin, amoxicillin clavulanate potassium, or trimethoprim‐sulfamethoxazole)
Trial: 8491934
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial medication
Trial: 3306809
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment combined with radiation
Trial: 27255874
Drug: S.A.L.T. device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S.A.L.T. device
Trial: 24825135
Drug: Praziquantel 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 3% ointment
Trial: 23586728
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg once daily for 56 days
Trial: 23586728
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 56 days
Trial: 28120446
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg
Trial: 17889580
Drug: Erdosteine 600
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 600 mg daily for 10 days
Trial: 17277852
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid withdrawal with tacrolimus (FK) and mycophenolate mofetil (MMF)
Trial: 17277852
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy with steroids, cyclosporine and azathioprine or steroids, FK and MMF (Control Group B)
Trial: 9001824
Drug: Broncho-Vaxom (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncho-Vaxom (one capsule daily, 10 days per month, for 3 consecutive months)
Trial: 1355099
Drug: Retinoic acid
RxNorm normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retinoic acid (0.1% cream) applied topically for 4 days
Trial: 1355099
Drug: Vehicle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle treatment applied topically for 4 days
Trial: 26979631
Drug: Single-nucleotide polymorphisms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-nucleotide polymorphisms related to matrix metalloproteinase-2 (MMP2), tissue inhibitor of matrix metalloproteinase-2 (TIMP2), and interleukin 16 (IL16)
Trial: 26979631
Drug: Single-nucleotide polymorphisms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-nucleotide polymorphisms related to MMP2, matrix metalloproteinase-1 (MMP1), and leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1)
Trial: 20191574
Drug: Pharmacologic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic and psychosocial treatment
Trial: 20191574
Drug: New medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New medications
Trial: 16084150
Drug: Tezosentan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours)
Trial: 12612363
Drug: Smoke-free Kids
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoke-free Kids programme (adequate treatment with at least three of five core modules)
Trial: 12612363
Drug: Smoke-free Kids
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoke-free Kids programme (adequate treatment)
Trial: 12612363
Drug: Smoke-free Kids
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoke-free Kids programme (all parents randomised to treatment)
Trial: 7195247
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg/kg, 2 x 20 mg/kg, or 3 x 20 mg/kg (phase II A trial)
Trial: 7195247
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 30 mg/kg (n=53), 1 x 40 mg/kg (n=45), 2 x 20 mg/kg (n=53) (phase II B trial)
Trial: 7195247
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg/kg (phase II A trial)
Trial: 7195247
Drug: Three oral
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three oral doses of 20 mg/kg given at 4-h intervals (phase II A trial)
Trial: 7195247
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg/kg (phase II B trial)
Trial: 17498487
Drug: General Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Western medicine therapy and differential treatment of traditional Chinese medicine (TCM) based on stage classification
Trial: 17498487
Drug: General Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Western medicine and placebo of traditional Chinese herbal medicine
Trial: 17498487
Drug: ADL (Activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL (Activity of daily living) scale
Trial: 12774471
Drug: Glimepiride (Amaril)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride (Amaril) combined with metformin, insulin, repaglynide, and nateglynide
Trial: 7775504
Drug: Morphine unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine unit (moderate to high doses of morphine)
Trial: 7775504
Drug: No-morphine unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-morphine unit (no morphine or morphine derivatives)
Trial: 2107240
Drug: Terfenadine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 1 mg/kg (mean dose, 69.6 ± 11.2 mg)
Trial: 2107240
Drug: Chlorpheniramine, 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 0.12 mg/kg (mean dose, 8.4 ± 1.3 mg)
Trial: 6777801
Drug: Ethanol at
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol at 0.76 ml kg‐1 (orally)
Trial: 6777801
Drug: Ethanol at
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol at 0.15 ml kg‐1
Trial: 26353009
Drug: Metyrapone monotherapy
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metyrapone monotherapy
Trial: 25177431
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of steroid and Korean red ginseng (KRG)
Trial: 25177431
Drug: KRG as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRG as an adjuvant to steroid therapy
Trial: 19523608
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral cholera vaccine VA1.3 (5 x 10(9) CFU)
Trial: 17530295
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus acidophilus 10(8) CFU/g 1 g b.i.d.)
Trial: 17530295
Drug: Antibiotics (trimethoprim/sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (trimethoprim/sulfamethoxazole 2/10 mg/kg h.s.)
Trial: 1922220
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of aspirin
Trial: 15026612
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of aspirin
Trial: 15026612
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of aspirin